Top Story

Phase 3 clinical trial enrollment begins for ocular allergy drug

November 30, 2015

Enrollment is underway for a second phase 3 clinical trial of Dextenza sustained release dexamethasone for treatment of allergic conjunctivitis, according to a press release from Ocular Therapeutix.

The prospective, randomized, double-masked, vehicle controlled, multicenter trial will evaluate safety and efficacy of the 0.4 mg bioresorbable intracanalicular depot in patients with chronic symptoms of allergic conjunctivitis.

Business News

Omeros reports $3.3 million in revenue in third quarter

November 30, 2015
Omeros reported $3.3 million in revenue in the third quarter, which includes $3.2 million in Omidria sales, according to a press release. The company reported $214,000…
Meeting News CoverageVideo

VIDEO: Shire emerges in areas of unmet need in ophthalmology

November 30, 2015
LAS VEGAS — At the American Academy of Ophthalmology annual meeting, Shire CEO Flemming Ornskov, MD, MPH, discusses the company's plans for progress and innovation in…
Meeting News CoverageVideo

VIDEO: Surgeon discusses learning curve of residents using femtosecond-assisted technology for cataract surgery

November 29, 2015
LAS VEGAS — At the American Academy of Ophthalmology annual meeting, Wallace Chamon, MD, discusses the learning curve of residents using the Catalys platform (Abbott…
Meeting News CoverageVideo

VIDEO: Study — Pretreatment with Fovista improves visual results in patients with neovascular

November 28, 2015
LAS VEGAS — At the American Academy of Ophthalmology annual meeting, Pravin Dugel, MD, discusses pilot study data in which vision improved in patients with neovascular…
More News Headlines »
Meeting News Coverage

Improvements in visual acuity with corneal inlay remain stable long-term

November 16, 2015
NEW ORLEANS – A study involving 253 subjects who received the Kamra corneal inlay in their nondominant eye showed…
More »

Arizona allows sale of adjustable focus eye wear without prescription

October 29, 2015
Arizona now permits the sale of adjustable eye wear without a prescription, based on a ruling by the assistant attorney…
More »

Allergan seeks approval for preservative-free Restasis

November 13, 2015
Allergan announced it has submitted a Prior Approval Supplement for Restasis 0.05% to obtain marketing clearance for a…
More »
Current Issues
View the Current Issue
Primary Care Optometry News